While Sarepta Therapeutics Inc has underperformed by -0.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SRPT fell by -8.74%, with highs and lows ranging from $159.89 to $55.25, whereas the simple moving average jumped by 13.33% in the last 200 days.
On January 31, 2024, BMO Capital Markets started tracking Sarepta Therapeutics Inc (NASDAQ: SRPT) recommending Outperform. Deutsche Bank also rated SRPT shares as ‘Buy’, setting a target price of $109 on the company’s shares in an initiating report dated December 12, 2023. Wedbush Initiated an Outperform rating on November 21, 2023, and assigned a price target of $224. Oppenheimer October 31, 2023d its ‘Outperform’ rating to ‘Perform’ for SRPT, as published in its report on October 31, 2023. Cantor Fitzgerald’s report from October 31, 2023 suggests a price prediction of $40 for SRPT shares, giving the stock a ‘Neutral’ rating. Evercore ISI also rated the stock as ‘In-line’.
Analysis of Sarepta Therapeutics Inc (SRPT)
Further, the quarter-over-quarter increase in sales is 53.54%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Sarepta Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -86.15% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.45, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and SRPT is recording an average volume of 1.06M. On a monthly basis, the volatility of the stock is set at 2.71%, whereas on a weekly basis, it is put at 2.60%, with a loss of -3.41% over the past seven days. Furthermore, long-term investors anticipate a median target price of $165.80, showing growth from the present price of $125.79, which can serve as yet another indication of whether SRPT is worth investing in or should be passed over.
How Do You Analyze Sarepta Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.98%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 86.85% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SRPT shares are owned by institutional investors to the tune of 86.85% at present.
